Effects of L-Carnitine Supplementation on Cardiovascular and Bone Turnover Markers in Patients With Pemphigus Vulgaris Under Corticosteroids Treatment: A Randomized, Double-Blind, Controlled Trial Publisher Pubmed



Yaghubi E¹ ; Daneshpazhooh M² ; Djalali M¹ ; Mohammadi H³ ; Sepandar F¹ ; Fakhri Z¹ ; Ghaedi E¹ ; Keshavarz SA⁴ ; Balighi K² ; Mahmoudi H² ; Zarei M¹ ; Javanbakht MH¹ Show Affiliations
Source: Dermatologic Therapy Published:2019

Abstract

Pemphigus vulgaris (PV) is a severe, bullous, autoimmune disease of the skin and mucous membranes. Corticosteroids are usually the main core treatment for controlling PV, which could lead to several side effects such as insulin resistance, osteoporosis, and cardiovascular disorders. The aim of this study is to evaluate the protective effects of l-carnitine (LC) supplementation in PV patients under corticosteroid treatment. In this randomized, double-blind, placebo-controlled clinical trial, 48 patients with PV were divided randomly into two groups to receive 2 g LC (n = 24) or a placebo (n = 24) for 8 weeks, respectively. Serum levels of osteopontin (OPN), bone morphogenic protein 4 (BMP4), cystatin C, systolic and diastolic blood pressure, 25 hydroxyvitamin D3, and LC were evaluated at the beginning and at the end of the study. LC supplementation demonstrated a significant increase in serum carnitine (p <.001). In addition, at the end of the trial, LC supplementation significantly decreased serum BMP4 (p =.003), OPN (p =.03), and cystatin C (p =.001) levels. There was no significant effect on blood pressure in comparison with the placebo. During study, no harmful side effects were reported by patients. These findings indicate that LC supplementation significantly leads to favorable changes in OPN, BMP4, and cystatin C in PV patients under corticosteroid therapy. However, further investigations are required to confirm these results. © 2019 Wiley Periodicals, Inc.